NCT02292225 2023-02-27
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
Phase 1 Terminated
Clinical Trials
4 trialsNCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01476657 2021-03-17
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
SecuraBio
Phase 1 Terminated
NCT04342117 2021-03-17
REAL
SecuraBio
Terminated